City Tx was founded by executives and scientists in RNAi, and launched in October 2024 alongside a $135 million Seried A financing round from leading life sciences investors. 

The American company is building a pipeline of innovative RNAi therapeutics to make a significant impact for patients across multiple therapeutic areas.